What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024
This mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from first-gener...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.23.176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849710996746141696 |
|---|---|
| author | Marcus M. Schittenhelm |
| author_facet | Marcus M. Schittenhelm |
| author_sort | Marcus M. Schittenhelm |
| collection | DOAJ |
| description | This mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from first-generation therapies such as midostaurin to second-generation agents such as gilteritinib, crenolanib and quizartinib. Midostaurin, the first FLT3-targeting therapy approved for newly diagnosed *FLT3*-mutated AML, laid the foundation for FLT3 inhibition by demonstrating survival benefits when combined with chemotherapy. Gilteritinib has emerged as a standard for relapsed/refractory (R/R) AML, crenolanib shows efficacy in post-transplant maintenance and quizartinib demonstrates promise in reducing frontline relapse risk. These advancements have improved outcome of *FLT3*-mutated AML in recent years while emphasizing the need for ongoing innovation to tackle relapse and resistance.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland
One anonymous peer reviewer
Received on December 20, 2024; accepted after peer review on March 07, 2025; published online on March 10, 2025. |
| format | Article |
| id | doaj-art-765611fcad6d48ecbba32936a5f0ee4b |
| institution | DOAJ |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-765611fcad6d48ecbba32936a5f0ee4b2025-08-20T03:14:45ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062025-03-0123110.36000/HBT.OH.2025.23.176What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024Marcus M. SchittenhelmThis mini review explores the evolution of FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy and the current treatment landscape for *FLT3*-mutated acute myeloid leukemia (AML), summarizing insights from the 66th Annual ASH Meeting and Exposition 2024. It highlights the transition from first-generation therapies such as midostaurin to second-generation agents such as gilteritinib, crenolanib and quizartinib. Midostaurin, the first FLT3-targeting therapy approved for newly diagnosed *FLT3*-mutated AML, laid the foundation for FLT3 inhibition by demonstrating survival benefits when combined with chemotherapy. Gilteritinib has emerged as a standard for relapsed/refractory (R/R) AML, crenolanib shows efficacy in post-transplant maintenance and quizartinib demonstrates promise in reducing frontline relapse risk. These advancements have improved outcome of *FLT3*-mutated AML in recent years while emphasizing the need for ongoing innovation to tackle relapse and resistance. PEER REVIEWED ARTICLE **Peer reviewers:** Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland One anonymous peer reviewer Received on December 20, 2024; accepted after peer review on March 07, 2025; published online on March 10, 2025.https://doi.org/10.36000/HBT.OH.2025.23.176 |
| spellingShingle | Marcus M. Schittenhelm What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 healthbook TIMES. Oncology Hematology |
| title | What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 |
| title_full | What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 |
| title_fullStr | What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 |
| title_full_unstemmed | What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 |
| title_short | What Does the Future Hold for the Treatment of FLT3-Mutated AML? News and Insights from ASH 2024 |
| title_sort | what does the future hold for the treatment of flt3 mutated aml news and insights from ash 2024 |
| url | https://doi.org/10.36000/HBT.OH.2025.23.176 |
| work_keys_str_mv | AT marcusmschittenhelm whatdoesthefutureholdforthetreatmentofflt3mutatedamlnewsandinsightsfromash2024 |